Home > Insider Trading > Filing (0001649094-24-000042)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649094	Vaxcyte Inc.	PCVX	Biological Products, (No Disgnostic Substances) (2836)	464233385

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1918033	Mikhail Eydelman	C/O Vaxcyte, Inc. 825 Industrial Road, Suite 300 San Carlos CA 94070	Svp, Gen Counsel & Corp Sec	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-08-01	1,667	$21.41	32,493	No	4	M	Direct
Common Stock	Disposition	2024-08-01	1,482	$78.80	31,011	No	4	S	Direct
Common Stock	Disposition	2024-08-01	185	$79.29	30,826	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-08-01	1,667	$0.00	1,667	$21.41

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
181,664		2032-05-08	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $78.23 to $79.22. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $79.23 to $79.34. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.